NexGel (NXGL) Q1 2026 earnings review
BioNX Acquisition Bails Out a Stalling Legacy Business
Q1 2026 marked a stark Reversing trend for NexGel's legacy operations. Revenue shrank 5.6% YoY to $2.65M—a dramatic deceleration from the 100%+ growth rates touted last year—driven by a collapse in the Silly George consumer brand. The volume drop crushed the bottom line, with operating loss widening to $958k and gross margins compressing to 40.0%. However, management has effectively hit the reset button. The mid-April acquisition of BioNX (Celularity's regenerative biomaterials portfolio) completely changes the company's trajectory. Armed with $13.8M in fresh capital and a partnership with Sequence LifeScience, NexGel projects pro forma revenue will triple to ~$35M and expects immediate profitability. The legacy struggles are now a sideshow to the regenerative medicine pivot.
🐂 Bull Case
The BioNX acquisition brings six established, commercial-stage regenerative products with existing reimbursement pathways. Pro forma annual revenue is guided to ~$35M, and management expects it to be immediately accretive to profitability, ending the legacy cash burn.
Sequence LifeScience led the $5.5M equity investment, replacing a short-term financial lender. Adding Sequence's leadership (Brian Kieser and Kevin Harris) to the Board provides vital manufacturing and distribution infrastructure to scale BioNX.
🐻 Bear Case
The core consumer and contract manufacturing business is Reversing. Total Q1 revenue fell 5.6%, Consumer Branded dropped 9%, and Contract Manufacturing dipped 3%. Gross margin compressed by 240 basis points to 40.0%.
To execute this pivot, NexGel had to raise $13.8M ($8.8M cash + $5M Celularity note) right as unrestricted cash plummeted to a perilous $208k at the end of Q1, triggering a Going Concern warning in the 10-Q.
⚖️ Verdict: ⚪
Neutral. The legacy business results were abysmal and contradicted previous growth narratives. However, the BioNX acquisition is legitimately transformative, providing the scale and margin profile NexGel desperately needed to survive.
Key Themes
The BioNX Pivot: From Consumer Lashes to Regenerative Medicine
NexGel is effectively a new company. By acquiring BioNX for $13.3M ($8.3M cash + $5M note), NexGel secures a portfolio of six commercial-stage biomaterials utilized in 500+ U.S. hospitals. Management appointed Dave Hazard as VP of Sales to build the commercial infrastructure. This shift to higher-margin, sticky hospital contracts fundamentally alters NexGel's margin profile, with management explicitly guiding for immediate profitability upon integration.
Silly George Brand Reversing Off a Cliff
A direct contradiction to the previously rosy consumer narrative: Silly George sales deteriorated severely. Total Consumer Branded revenue fell 9% YoY from $1.78M to $1.62M. Management blamed an 'uncharacteristically bad fourth quarter' and a 'meh first quarter' amid intense competition in pop-on lashes. The legacy growth engine has stalled completely.
The Silent Disappearance of AbbVie RESONIC
In Q1 2025 and Q2 2025, management repeatedly highlighted the AbbVie RESONIC device (for which NexGel is the exclusive gel pad supplier) as a 'substantial opportunity,' despite delays. In the Q1 2026 call and 10-Q, AbbVie is completely absent. Investors should view this potential catalyst as dead until proven otherwise.
Innovative Optics Laser Plume Validation
A key technological milestone was achieved: the IRB study with Innovative Optics was published, proving NexGel's hydrogel reduces carcinogenic plume during laser hair removal by 96%, alongside secondary pain reduction benefits. Innovative Optics is now actively marketing this to major laser manufacturers, unlocking a net-new commercial vertical.
Cash Burn Forced Heavy Dilution
The 10-Q paints a bleak picture of the standalone entity: Q1 ended with just $208k in unrestricted cash, generating a Going Concern warning. The company burned $504k in operating cash. To fund the BioNX deal and survive, NexGel issued $7.37M in 10% convertible notes and warrants, plus another $1.21M in May, causing massive dilution to the legacy shareholder base.
Upgrading the Financial and Sales Guardrails
Recognizing the need for operational maturity to handle a $35M run-rate business, NexGel overhauled its executive suite. Ian Blackman was brought in as CFO specifically for M&A integration and scaling, replacing former leadership. The addition of Sequence LifeScience executives to the Board also provides desperately needed operational oversight.
Other KPIs
Decelerating. Down from 42.4% in the prior year period. The decline in high-margin Silly George volume directly impacted absorption of fixed facility costs, proving that the legacy business lacks operating leverage when consumer demand wavers.
Accelerating slightly (+2.8% YoY). Management attributed the rise primarily to professional and consulting fees related to the BioNX acquisition and settling a legal dispute with Kiss Nail Products, offsetting a $6k drop in advertising/marketing.
Accelerating. Up 48% YoY from $76k. While still a fraction of the business, this was the only segment to exhibit growth in Q1, offering a small silver lining to the legacy operations.
Guidance
Accelerating massively. Management expects the BioNX acquisition to roughly triple the company's historical revenue run-rate. Given legacy FY25 guidance was $13M, this implies the BioNX assets generate roughly $22M annually.
Stable expectation. CFO Ian Blackman guided that the new BioNX operations will carry an approximate $500,000 monthly all-in operating expense (salaries, marketing, commissions). This equates to a $1.5M quarterly drag, which management expects will be more than offset by immediate gross profit accretion from the new assets.
Key Questions
BioNX Integration Friction
Given the 'lag in getting the sales force reengaged' due to Sunshine Laws and hospital vendor changes, what is the exact timeline for BioNX revenue to reach its historical run-rate under NexGel's umbrella?
AbbVie RESONIC Status
The AbbVie partnership was heavily promoted in 2024 and 2025 but completely omitted from the Q1 2026 update. Has this partnership been officially terminated, or is it permanently stalled?
Legacy Consumer Strategy
With Silly George sales contracting and the company now laser-focused on hospital-grade regenerative medicine, is management considering divesting the consumer portfolio to focus entirely on BioNX?